In prostate cancer, CTC counts have been associated with prognosis and importantly, isolated CTCs can function as a surrogate tumour samples to detect therapy-determining biomarkers, including the mRNA based androgen receptor variant AR-V7 in CTCs [5,6,7,8]. This evidence concerns the gene AR and prostate carcinoma.